@article{3ade0b994e5742299db30a71c62ecd21,
title = "Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI A+T+) in a population-based sample",
abstract = "Introduction: This study evaluated the diagnostic accuracy of the Cogstate Brief Battery (CBB) for mild cognitive impairment (MCI) and prodromal Alzheimer's disease (AD) in a population-based sample. Methods: Participants included adults ages 50+ classified as cognitively unimpaired (CU, n = 2866) or MCI (n = 226), and a subset with amyloid (A) and tau (T) positron emission tomography who were AD biomarker negative (A–T–) or had prodromal AD (A+T+). Results: Diagnostic accuracy of the Learning/Working Memory Composite (Lrn/WM) for discriminating all CU and MCI was moderate (area under the curve [AUC] = 0.75), but improved when discriminating CU A–T– and MCI A+T+ (AUC = 0.93) and when differentiating MCI participants without AD biomarkers from those with prodromal AD (AUC = 0.86). Conventional cut-offs yielded lower than expected sensitivity for both MCI (38%) and prodromal AD (73%). Discussion: Clinical utility of the CBB for detecting MCI in a population-based sample is lower than expected. Caution is needed when using currently available CBB normative data for clinical interpretation.",
keywords = "Alzheimer's disease, amyloid, cognigram, memory, mild cognitive impairment, neuropsychology, one back, one card learning, sensitivity and specificity, tau",
author = "Alden, {Eva C.} and Pudumjee, {Shehroo B.} and Lundt, {Emily S.} and Albertson, {Sabrina M.} and Machulda, {Mary M.} and Kremers, {Walter K.} and Jack, {Clifford R.} and Knopman, {David S.} and Petersen, {Ronald C.} and Mielke, {Michelle M.} and Stricker, {Nikki H.}",
note = "Funding Information: The authors wish to thank the participants and staff at the Mayo Clinic Study of Aging. This work was supported by the Rochester Epidemiology Project (R01 AG034676), the National Institutes of Health (grant numbers P50 AG016574, P30 AG062677, U01 AG006786, R37 AG011378, R01 AG041851, RF1 AG55151), a grant from the Alzheimer's Association (AARG‐17‐531322), Zenith Award from the Alzheimer's Association, the Robert Wood Johnson Foundation, The Elsie and Marvin Dekelboum Family Foundation, Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic, Liston Award, Schuler Foundation, GHR Foundation, AVID Radiopharmaceuticals, and the Mayo Foundation for Education and Research. We would like to greatly thank AVID Radiopharmaceuticals, Inc., for their support in supplying AV‐1451 precursor, chemistry production advice and oversight, and FDA regulatory cross‐filing permission and documentation needed for this work. NHS and MMMi serve as consultants to Biogen and Lundbeck. DSK serves on a Data Safety Monitoring Board for the DIAN‐TU study and is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen, and the University of Southern California. RCP has served as a consultant for Hoffman‐La Roche Inc., Merck Inc., Genentech Inc., Biogen Inc., Eisai, Inc., and GE Healthcare. Funding Information: The authors wish to thank the participants and staff at the Mayo Clinic Study of Aging. This work was supported by the Rochester Epidemiology Project (R01 AG034676), the National Institutes of Health (grant numbers P50 AG016574, P30 AG062677, U01 AG006786, R37 AG011378, R01 AG041851, RF1 AG55151), a grant from the Alzheimer's Association (AARG-17-531322), Zenith Award from the Alzheimer's Association, the Robert Wood Johnson Foundation, The Elsie and Marvin Dekelboum Family Foundation, Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic, Liston Award, Schuler Foundation, GHR Foundation, AVID Radiopharmaceuticals, and the Mayo Foundation for Education and Research. We would like to greatly thank AVID Radiopharmaceuticals, Inc., for their support in supplying AV-1451 precursor, chemistry production advice and oversight, and FDA regulatory cross-filing permission and documentation needed for this work. NHS and MMMi serve as consultants to Biogen and Lundbeck. DSK serves on a Data Safety Monitoring Board for the DIAN-TU study and is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen, and the University of Southern California. RCP has served as a consultant for Hoffman-La Roche Inc., Merck Inc., Genentech Inc., Biogen Inc., Eisai, Inc., and GE Healthcare. Publisher Copyright: {\textcopyright} 2021 the Alzheimer's Association",
year = "2021",
month = apr,
doi = "10.1002/alz.12219",
language = "English (US)",
volume = "17",
pages = "584--594",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "4",
}